Artgen Biotech PJSC (MOEX:ISKJ)
Russia flag Russia · Delayed Price · Currency is RUB
59.54
+0.84 (1.43%)
At close: Jul 8, 2022

Artgen Biotech PJSC Financials Overview

Millions RUB. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,7161,7161,5211,3691,1371,181
Revenue Growth
6.25%12.80%11.18%20.38%-3.72%8.93%
Gross Profit
1,1041,1041,082974.09670.34719.4
Operating Income
131.9131.9299.62275.3697.46130.42
Net Income
96.9596.95214.91168.8646.1211.63
Earnings Per Share
1.291.292.891.820.530.15
EPS Growth
-51.45%-55.36%58.79%243.40%264.54%-85.01%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
730.49730.49538.46572.33227.06193.8
Total Debt
964.99964.99737.65786.96831.6617.13
Net Cash (Debt)
-234.5-234.5-199.2-214.62-604.55-423.33
Net Cash Growth
------
Net Cash Per Share
-3.12-3.12-2.68-2.32-6.96-5.29

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
190.75190.75481.83434.85220.3280.8
Capital Expenditures
-170.39-170.39-99.68-204.29-135.93-153.3
Free Cash Flow
20.3620.36382.16230.5684.37127.51
Free Cash Flow Growth
-93.44%-94.67%65.75%173.26%-33.83%-

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
64.34%64.34%71.13%71.18%58.96%60.92%
Operating Margin
7.69%7.69%19.69%20.12%8.57%11.04%
Pretax Margin
4.98%4.98%14.29%15.45%2.58%2.49%
Profit Margin
5.65%5.65%14.12%12.34%4.06%0.98%
FCF Margin
1.19%1.19%25.12%16.85%7.42%10.80%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
46.16-20.4826.1792.95711.21
P/FCF Ratio
210.58-11.5219.1750.8064.88
PS Ratio
2.50-2.893.233.777.01